High Response Rates to Crizotinib in Advanced, Chemoresistant ALK-Positive Lymphoma
Redaelli S et al. High response rates to crizotinib in advanced, chemoresistant ALK+ lymphoma patients. Proc ASH 2013; Abstract 368.
Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Lymphoma Program and Interim Director at Tufts Cancer Center in Boston, Massachusetts.
|